Fresenius Medical Care, the world’s largest provider of dialysis products and services, has successfully refinanced its existing senior secured credit agreement, originally maturing in 2019.
The amended credit agreement now reflects a simplified, unsecured structure consistent with the investment grade rating of the company and lower tiered pricing. The new structure should also enable future bond issuances to be ranked pari passu with the credit agreement.
The new facility has an aggregate amount of approximately USD 3.9 billion and consists of revolving facilities and term loans, both U.S. Dollar and Euro denominated with maturities in 2020 and 2022.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.